CoChat

The Antiresorptive Effects of a Single Dose of Zoledronate Persist for Two Years: A Randomized, Placebo-Controlled Trial in Osteopenic Postmenopausal Women

Grey, Andrew, Bolland, Mark J., Wattie, Diana, Horne, Anne, Gamble, Greg, Reid, Ian R. · 2009 · The Journal of Clinical Endocrinology & Metabolism
Cited by 110

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Context: Annual iv administration of 5 mg zoledronate decreases fracture risk. The optimal dosing interval of 5 mg zoledronate is not known. Objective: Our objective was to determine the duration of antiresorptive action of a single 5-mg dose of iv zoledronate. Design, Setting, and Participants: We conducted a double-blind, randomized, placebo-controlled trial over 2 yr at an academic research center, in a volunteer sample of 50 postmenopausal women with osteopenia. Intervention: Intervention included 5 mg zoledronate. Main Outcome Measures: Biochemical markers of bone turnover and bone mineral density of the lumbar spine, proximal femur, and total body. Results: Compared with placebo, zoledronate treatment decreased mean levels of each of four markers of bone turnover by at least 38% (range 38–45%) for the duration of the study (P < 0.0001 for each marker). After 2 yr, bone mineral density was higher in the zoledronate group than the placebo group by an average of 5.7% (95% confidence interval = 4.0–7.4) at the lumbar spine, 3.9% (2.2–5.7) at the proximal femur, and 1.7% (0.8–2.5) at the total body (P < 0.0001 for each skeletal site). Between-groups differences in markers of bone turnover and bone mineral density were similar at 12 and 24 months. Mild secondary hyperparathyroidism was present throughout the study in the zoledronate group. Conclusion: The antiresorptive effects of a single 5-mg dose of zoledronate are sustained for at least 2 yr. The magnitudes of the effects on markers of bone turnover and bone mineral density are comparable at 12 and 24 months. Administration of zoledronate at intervals of up to 2 yr may be associated with antifracture efficacy; clinical trials to investigate this possibility are justified.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2008-2241

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 14

  1. Reid, 2002, Intravenous zoledronic acid in postmenopausal women with low bone mineral density., N Engl J Med, 346, 653, 10.1056/NEJMoa011807 · DOI · Paper page
  2. Devogelaer, 2007, Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis., Osteoporos Int, 18, 1211, 10.1007/s00198-007-0367-3 · DOI
  3. Bolland, 2008, Effects of intravenous zoledronate on bone turnover and BMD persist for at least 24 months., J Bone Miner Res, 23, 1304, 10.1359/jbmr.080312 · DOI
  4. Thiébaud, 1997, Effects of ibandronate i.v, bolus injection in healthy men and postmenopausal women. J Bone Miner Res, 12, S343
  5. Borba, 2007, Bone turnover 18 months after a single intravenous dose of zoledronic acid., Int J Clin Pract, 61, 1058, 10.1111/j.1742-1241.2007.01392.x · doi:10.1111/j.1742-1241.2007.01392.x
  6. Brown, 2007, Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid., Clin Cancer Res, 13, 5406, 10.1158/1078-0432.CCR-07-0247 · DOI
  7. Recker, 2008, Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure., J Bone Miner Res, 23, 6, 10.1359/jbmr.070906 · DOI · Paper page
  8. Chavassieux, 1997, Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis., J Clin Invest, 100, 1475, 10.1172/JCI119668 · DOI · Paper page
  9. Eriksen, 2002, Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis., Bone, 31, 620, 10.1016/S8756-3282(02)00869-4 · DOI · Paper page
  10. Recker, 2004, Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study., Osteoporos Int, 15, 231, 10.1007/s00198-003-1530-0 · DOI
  11. Iida-Klein, 2007, Effects of cyclic vs. daily treatment with human parathyroid hormone (1–34) on murine bone structure and cellular activity., Bone, 40, 391, 10.1016/j.bone.2006.09.010 · DOI
  12. Kim, 2003, Trabecular bone response to mechanical and parathyroid hormone stimulation: the role of mechanical microenvironment., J Bone Miner Res, 18, 2116, 10.1359/jbmr.2003.18.12.2116 · DOI
  13. Rubin, 2002, The anabolic effects of parathyroid hormone., Osteoporos Int, 13, 267, 10.1007/s001980200026 · DOI
  14. Cramer, 2007, A systematic review of persistence and compliance with bisphosphonates for osteoporosis., Osteoporos Int, 18, 1023, 10.1007/s00198-006-0322-8 · DOI · Paper page

Cited by

See all 110

Metadata

Authors
Grey, A., Bolland, M. J., Wattie, D., Horne, A., Gamble, G., & Reid, I. R.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2009-02-01
Volume
94
Issue
2
Pages
538-544
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2081378515
Cited by
110
References
5
FWCI
9.74
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Antiresorptive Effects of a Single Dose of Zoledronate Persist for Two Years: A Randomized, Placebo-Controlled Trial in Osteopenic Postmenopausal Women. https://app.cochat.ai/papers/10.1210/jc.2008-2241
The paper
Grey, A., Bolland, M. J., Wattie, D., Horne, A., Gamble, G., & Reid, I. R. (2009). The Antiresorptive Effects of a Single Dose of Zoledronate Persist for Two Years: A Randomized, Placebo-Controlled Trial in Osteopenic Postmenopausal Women. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2008-2241

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.